OBJECTIVE： To observe clinical efficacy and safety of salmeterol and fluticasone propionate in the treatment of moderate and severe bronchial asthma. METHODS： 98 patients with moderate and severe bronchial asthma were selected from our hospital were included in the study and were randomly divided into control group （49 cases， 3 cases withdrew from the test and 46 cases completed the test） and observation group （49 cases， 2 cases withdrew from the test and 47 cases completed the test）. Control group was given Budesonide aerosol preparation， 1 dose， bid； observation group was given Salmeterol and fluticasone propionate inhalation， 1 dose， bid. The treatment course lasted for 2 months. Clinical efficacy， lung function indexes， the time of clinical symptom disappearance， FEV1， PD20， ACT score， asthma attack times within half an year， EO％ and ECP in serum and sputum， and the occurrence of ADR were compared between 2 groups. RESULTS： After treatment， total effective rate of observation group was significantly higher than that of control group （95.73％ vs. 76.09％）； FVC， FEV1 and PEF and other indexes of 2 groups were increased significantly， and the observation group was significantly higher than the control group； the disappearance time of pulmonary rales， wheezing， dyspnea and cough in observation group were significantly shorter than in control group； PD20 and ACT score of 2 groups were significantly increased， ACT score of observation group was significantly higher than that of control group； EO％ and ECP in serum and sputum of observation group were significantly lower than those of control group， there was statistical significance （P＜0.05）. Asthma attack times within half an year in observation was less than control group， there was no statistical significance （P＞0.05）. All ADRs disappeared after drug withdrawal. CONCLUSIONS： Therapeutic efficacy of salmeterol and fluticasone propionate is better than budesonide in the treatment of moderate and severe bronchial asthma， and can effectively improve lung function， shorten the time of clinical symptoms disapperance and reduce the level of inflammatory factor with and good safety.